vs
Side-by-side financial comparison of Archer Daniels Midland (ADM) and BROOKFIELD Corp (BN). Click either name above to swap in a different company.
Archer Daniels Midland is the larger business by last-quarter revenue ($20.5B vs $18.1B, roughly 1.1× BROOKFIELD Corp). BROOKFIELD Corp runs the higher net margin — 5.8% vs 1.5%, a 4.4% gap on every dollar of revenue.
The Archer-Daniels-Midland Company, commonly known as ADM, is an American multinational food processing and commodities trading corporation founded in 1902 and headquartered in Chicago, Illinois. The company operates more than 270 plants and 420 crop procurement facilities worldwide, where cereal grains and oilseeds are processed into products used in food, beverage, nutraceutical, industrial, and animal feed markets worldwide.
Brookfield Properties is a North American subsidiary of commercial real estate firm Brookfield Property Partners, which itself is a subsidiary of alternative asset management company Brookfield Corporation. It is responsible for the asset management of the company's real estate portfolio, including office, multi-family residential, retail, hospitality, and logistics buildings.
ADM vs BN — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.5B | $18.1B |
| Net Profit | $298.0M | $1.1B |
| Gross Margin | 6.0% | — |
| Operating Margin | — | — |
| Net Margin | 1.5% | 5.8% |
| Revenue YoY | 1.6% | — |
| Net Profit YoY | 1.0% | — |
| EPS (diluted) | $0.62 | $0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $20.5B | — | ||
| Q4 25 | $6.1B | — | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.3B | $18.1B | ||
| Q1 25 | $6.1B | — | ||
| Q4 24 | $-25.7B | — | ||
| Q3 24 | $6.0B | — | ||
| Q2 24 | $22.2B | — |
| Q1 26 | $298.0M | — | ||
| Q4 25 | $456.0M | — | ||
| Q3 25 | $108.0M | — | ||
| Q2 25 | $219.0M | $1.1B | ||
| Q1 25 | $295.0M | — | ||
| Q4 24 | $567.0M | — | ||
| Q3 24 | $18.0M | — | ||
| Q2 24 | $486.0M | — |
| Q1 26 | 6.0% | — | ||
| Q4 25 | 20.0% | — | ||
| Q3 25 | 19.8% | — | ||
| Q2 25 | 21.6% | — | ||
| Q1 25 | 19.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 22.8% | — | ||
| Q2 24 | 6.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 7.9% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 4.4% | — | ||
| Q1 25 | 5.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 2.7% | — |
| Q1 26 | 1.5% | — | ||
| Q4 25 | 7.5% | — | ||
| Q3 25 | 1.7% | — | ||
| Q2 25 | 3.5% | 5.8% | ||
| Q1 25 | 4.8% | — | ||
| Q4 24 | -2.2% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 2.2% | — |
| Q1 26 | $0.62 | — | ||
| Q4 25 | $0.95 | — | ||
| Q3 25 | $0.22 | — | ||
| Q2 25 | $0.45 | $0.15 | ||
| Q1 25 | $0.61 | — | ||
| Q4 24 | $1.21 | — | ||
| Q3 24 | $0.04 | — | ||
| Q2 24 | $0.98 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $591.0M | $13.7B |
| Total DebtLower is stronger | $1.7B | — |
| Stockholders' EquityBook value | $22.8B | $161.6B |
| Total Assets | — | $506.1B |
| Debt / EquityLower = less leverage | 0.08× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $591.0M | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.1B | $13.7B | ||
| Q1 25 | $864.0M | — | ||
| Q4 24 | $611.0M | — | ||
| Q3 24 | $784.0M | — | ||
| Q2 24 | $764.0M | — |
| Q1 26 | $1.7B | — | ||
| Q4 25 | $7.6B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.3B | — | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | — | — |
| Q1 26 | $22.8B | — | ||
| Q4 25 | $22.7B | — | ||
| Q3 25 | $22.5B | — | ||
| Q2 25 | $22.4B | $161.6B | ||
| Q1 25 | $22.1B | — | ||
| Q4 24 | $22.2B | — | ||
| Q3 24 | $22.0B | — | ||
| Q2 24 | $22.2B | — |
| Q1 26 | — | — | ||
| Q4 25 | $52.4B | — | ||
| Q3 25 | $51.9B | — | ||
| Q2 25 | $52.0B | $506.1B | ||
| Q1 25 | $53.4B | — | ||
| Q4 24 | $53.3B | — | ||
| Q3 24 | $52.2B | — | ||
| Q2 24 | $52.7B | — |
| Q1 26 | 0.08× | — | ||
| Q4 25 | 0.33× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.37× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $2.0B |
| Free Cash FlowOCF − Capex | — | $-745.0M |
| FCF MarginFCF / Revenue | — | -4.1% |
| Capex IntensityCapex / Revenue | 0.9% | 15.2% |
| Cash ConversionOCF / Net Profit | — | 1.91× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-313.0M | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $4.3B | $2.0B | ||
| Q1 25 | $-342.0M | — | ||
| Q4 24 | $322.0M | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $468.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-669.0M | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $4.0B | $-745.0M | ||
| Q1 25 | $-633.0M | — | ||
| Q4 24 | $-170.0M | — | ||
| Q3 24 | $919.0M | — | ||
| Q2 24 | $106.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | -11.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 63.0% | -4.1% | ||
| Q1 25 | -10.3% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 15.3% | — | ||
| Q2 24 | 0.5% | — |
| Q1 26 | 0.9% | — | ||
| Q4 25 | 5.9% | — | ||
| Q3 25 | 4.6% | — | ||
| Q2 25 | 4.8% | 15.2% | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | -1.9% | — | ||
| Q3 24 | 6.4% | — | ||
| Q2 24 | 1.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.69× | — | ||
| Q3 25 | 16.75× | — | ||
| Q2 25 | 19.63× | 1.91× | ||
| Q1 25 | -1.16× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 72.22× | — | ||
| Q2 24 | 0.96× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADM
| Ag Services and Oilseeds | $16.0B | 78% |
| Carbohydrate Solutions | $2.6B | 12% |
| Nutrition | $1.8B | 9% |
BN
Segment breakdown not available.
